

Gibson Dunn Advised Shareholders in Connection with Sale of Aicuris to Asahi Kasei

Firm News | February 27, 2026

Gibson Dunn advised the shareholders in connection with the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, through its subsidiary Veloxis Pharmaceuticals, Inc. The acquisition price amounts to 780 million euros (approximately \$920 million USD).

Our M&A team was led by partners Dr. Dirk Oberbracht and Sonja Ruttmann and included partner Ryan Murr, of counsel Dr. Alireza Fatemi, and associates Simon Stöhlker, Andreas Rief, Tim Windfelder, and David Lübkeimeier. Partners Dr. Lars Petersen and Kai Gesing and associate Yannick Oberacker advised on regulatory and antitrust issues. Partners Benjamin Rapp and Sean Feller and associates Daniel Reich and Nicolas von Wallis advised on tax. Of counsel Dr. Peter Gumnior advised on labor law aspects.

Related People

[Dirk Oberbracht](#)

[Sonja Ruttmann](#)

[Ryan A. Murr](#)

[Alireza Fatemi](#)

[Simon Stöhlker](#)

[Andreas Rief](#)

[Tim Windfelder](#)

[David Lübkeimeier](#)

[Lars Petersen](#)

[Kai Gesing](#)

[Yannick Oberacker](#)

[Sean C. Feller](#)

[Peter Gumnior](#)

Related Capabilities

[Mergers and Acquisitions](#)